Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

Table 2 Responses in the intention-to-treat population

	Independent centralized review
ORR (95%CI)	37.8(26.8–49.9)
CR	3(4.1)
VGPR	5(6.8)
PR	20(27.0)
SD	32(43.2)
PD	5(6.8)
Not evaluable	9(12.1)^a
TTR, months	1.84(0.95–2.35)
Median (95%CI) DOR	8.8(6.0–14.7)

CR complete response, DCR disease control rate, DOR duration of remission, ORR overall response rate, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TTR time to treatment response, VGPR very good PR
^aThe patients were not evaluable as they failed to complete one cycle of treatment

ISSN: 1471-2407